[Bone marrow plasma concentrations of Dickkopf1 in patients with multiple myeloma].
To detect bone marrow plasma concentrations of Dickkopf1 (DKK1) in patients with multiple myeloma (MM) and to investigate its clinical significance. Bone marrow plasma DKK1 levels were quantified in 80 newly diagnosed MM patients, 10 monoclonal gammopathy of undetermined significance (MGUS) patients and 20 control subjects by ELISA, using a monoclonal anti-DKK1 antibody. Bone marrow plasma DKK1 was elevated in MM as compared with MGUS[(9.3588 +/-7.9441)ng/ml with compared (1.7620 +/-0.7529)ng/ml, P=0.001]. There was no difference between MGUS patients and control subjects [(1.7620 +/-0.7529)ng/ml with compared (1.2491 +/- 0.6990)ng/ml, P>0.05]. Bone marrow plasma DKK1 levels were correlated with myeloma Durie and Salmon stages [(2.4410 +/-0.6583)ng/ml of stage I with compared (10.3471 +/-8.0169)ng/ml of stage II/III, P=0.002]. There was no difference between MM patients in stage I and MGUS patients (P>0.05). Myeloma patients without lytic lesions in conventional radiography had significantly lower DKK1 levels than patients with lytic bone disease [(2.4348 +/-0.6634)ng/ml with compared 11.2272 +/-7.9753)ng/ml, P<0.001]. Bone marrow plasma DKK1 levels were correlated with the number of bone lesions, 0 with compared 1-3 with compared >3 lesions: (2.4348 +/-0.6634)ng/ml, (4.9845 +/-0.5852)ng/ml, (15.3342 +/-7.9187)ng/ml (P<0.001). Myeloma patients have increased bone marrow plasma DKK1 as compared with patients with MGUS and control subjects.Bone marrow plasma concentrations of DKK1 have close relationship with myeloma stage and lytic bone disease.